Patent ID: 8293240
Filing Date: 2012-10-23
Classification: A61K,A61P,C07K

Abstract:
1. A method, comprising: administering; to a subject having a drug-resistant cancer, a therapeutically acceptable amount of a composition of a fatty acid metabolism inhibitor and a pharmaceutically acceptable carrier wherein the subject is not otherwise indicated for treatment with the compound and further comprising administering a glucose metabolism inhibitor and optionally one or more of the chemotherapeutic agents selected from the group consisting of methotrexate, trimetrexate, adriamycin, taxotere, doxorubicin, 5-flurouracil, vincristine, vinblastine, pamidronate disodium, anastrozole, exemestane, cyclophosphamide, epirubicin, toremifene, letrozole, trastuzumab, megestrol, tamoxifen, paclitaxet, docetaxel, capecitabine, and goserelin acetate, wherein the subject is not administered another anti-cancer agent for treating the cancer other than the fatty acid metabolism inhibitor, the glucose metabolism inhibitor and the chemotherapeutic, and wherein the composition is formulated in a colloidal dispersion system that is a liposome.